Surprisingly, all of these gene signatures were found to be significantly enriched in ELAVL2-low GBM patients in these GBM cohorts (Fig. 4b), enabling us to hypothesize that ELAVL2 might negatively control the expression of MES-related molecules. Here, ELAVL2 is linked to glioblastoma.